Medical alert: hemolytic anemia in Crixivan cohort. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Medical alert: hemolytic anemia in Crixivan cohort. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Crit Path AIDS Proj. 1997 Summer;(No 32):28-9. Unique Identifier : AIDSLINE MED/97702728

Abstract: Merck is adding a warning label to indinavir (Crixivan) as a result of 20 cases of hemolytic anemia reported among the 140,000 people currently using the drug. The disease causes a premature destruction of red blood cells, and the most common symptoms are fatigue, jaundice and discolored urine. The condition progresses rapidly and requires quick treatment. Mild cases are treated by stopping the drug, moderate cases are treated with the corticosteroid prednisone, and severe cases may require blood transfusions.

Keywords: *Anemia, Hemolytic/CHEMICALLY INDUCED *HIV Protease Inhibitors/ADVERSE EFFECTS *Indinavir/ADVERSE EFFECTS
971230
M97C1587

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .